Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. GSK is nearing a $1bn deal to buy a US biotech developing a treatment for rare gastrointestinal tumours ...

Three major pharmaceutical companies—AstraZeneca, Boehringer Ingelheim, and GSK—have announced plans ... affected by this ...

Global pharma major Lupin Limited (Lupin) announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for ...

For example, Boehringer Ingelheim has dropped the price of its asthma medication Atrovent HFA by 35%. In 2023, the German drugmaker, along with its rivals, such as AbbVie (ABBV), GSK (GSK), and ...